share_log

Altamira Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Thomas Meyer(1.2%)

Altamira Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Thomas Meyer(1.2%)

Altamira Therapeutics | SC 13D/A：超過5%持股股東披露文件(修正)-Thomas Meyer(1.2%)
SEC announcement ·  03/13 23:08
牛牛AI助理已提取核心訊息
Thomas Meyer, an investor in Altamira Therapeutics, has filed an amendment to his Schedule 13D with the U.S. Securities and Exchange Commission, disclosing recent purchases of the company's common stock. The amendment, dated March 13, 2024, reports that Meyer now beneficially owns 22,297 common shares of Altamira Therapeutics, which represents 1.2% of the company. This stake includes 20,000 common shares and the right to acquire an additional 2,297 shares through options and warrants exercisable within 60 days. The filing details two separate transactions: the purchase of 51 common shares on December 29, 2023, at $3.24 per share, and 17,350 common shares on March 11, 2024, at $1.864 per share, both funded with personal funds. Meyer holds sole voting and dispositive power over these shares. The amendment to Schedule 13D does not alter any previously reported information except as explicitly stated.
Thomas Meyer, an investor in Altamira Therapeutics, has filed an amendment to his Schedule 13D with the U.S. Securities and Exchange Commission, disclosing recent purchases of the company's common stock. The amendment, dated March 13, 2024, reports that Meyer now beneficially owns 22,297 common shares of Altamira Therapeutics, which represents 1.2% of the company. This stake includes 20,000 common shares and the right to acquire an additional 2,297 shares through options and warrants exercisable within 60 days. The filing details two separate transactions: the purchase of 51 common shares on December 29, 2023, at $3.24 per share, and 17,350 common shares on March 11, 2024, at $1.864 per share, both funded with personal funds. Meyer holds sole voting and dispositive power over these shares. The amendment to Schedule 13D does not alter any previously reported information except as explicitly stated.
Altamira Therapeutics的投資者托馬斯·邁耶已向美國證券交易委員會提交了附表13D的修正案，披露了最近購買該公司普通股的情況。該修正案於2024年3月13日發佈，報告稱，邁耶現在實益擁有Altamira Therapeutics的22,297股普通股，佔該公司1.2％的股份。該股份包括20,000股普通股以及通過可在60天內行使的期權和認股權證額外收購2,297股的權利。該文件詳細介紹了兩筆單獨的交易：2023年12月29日以每股3.24美元的價格購買51股普通股，以及2024年3月11日以每股1.864美元的價格購買17,350股普通股，均由個人資金資助。邁耶對這些股票擁有唯一的投票權和處置權。除非另有明確說明，否則附表13D的修正不會改變任何先前報告的信息。
Altamira Therapeutics的投資者托馬斯·邁耶已向美國證券交易委員會提交了附表13D的修正案，披露了最近購買該公司普通股的情況。該修正案於2024年3月13日發佈，報告稱，邁耶現在實益擁有Altamira Therapeutics的22,297股普通股，佔該公司1.2％的股份。該股份包括20,000股普通股以及通過可在60天內行使的期權和認股權證額外收購2,297股的權利。該文件詳細介紹了兩筆單獨的交易：2023年12月29日以每股3.24美元的價格購買51股普通股，以及2024年3月11日以每股1.864美元的價格購買17,350股普通股，均由個人資金資助。邁耶對這些股票擁有唯一的投票權和處置權。除非另有明確說明，否則附表13D的修正不會改變任何先前報告的信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。